(Jinan, China, and Princeton, NJ) KBP BioSciences, a clinical stage biopharma company announced today that the first patient with chronic kidney disease has received its lead compound, KBP-5074 in a Phase Ib/IIa trial.
Millions of people suffer from chronic kidney disease (CKD) and end stage renal disease (ESRD), which causes not only significant suffering of the patients, but also very high mortality rate. KBP-5074 is a non-steroidal, highly selective mineralcorticoid receptor antagonist (MRA) that has shown promising results in pre-clinical and clinical results for kidney and heart impairments. “We spent a lot of time thinking where KBP-5074 best fits in. A drug that we believe is efficacious and safe for organ-impaired patients.” Said Dr. Zhenhua Huang, President and founder of KBP. “We decided to target renal ailments, where few drugs are available due to the high risk nature of the disease.”
About KBP BioSciences
KBP BioSciences is a clinical stage biotech company dedicated to research, development and commercialization of new medicines for the global market. Through its efficient discovery-development platform, KBP has developed a deep pipeline focused on organ protection, antibiotics, and inflammation. KBP has 3 clinical stage compounds: KBP-5074 (cardio-renal disease), KBP-7072 (multi-drug resistant bacteria), and KBP-7026 (COPD/Asthma).
The management team of KBP has decades of combined experience in drug development. The company is headquartered in Jinan, China, and has it clinical research center in Princeton, NJ.
Invented in China for the world.